23/09/2010 Urology Network Meeting Prostate and Bladder Cancer RLU/BGH Joint Clinic Presented by: Dr Z Malik.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Karen Pocock Skin Cancer Clinical Nurse Specialist
Is Radical Prostatectomy Adequate For High Risk Prostate Cancer?
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Management of locally advanced & metastatic prostate cancer Dr. Purvish. M. Parikh MD, DNB, PhD, FICP Professor & Head Department of Medical Oncology Tata.
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Merseyside and Cheshire Cancer Network HEPATO BILIARY MULTIDISCIPLINIARY TEAM MEETING Referral to Specialist HPB (Liver) MDT, University Hospital, Aintree,
British Association of Urological Surgeons Metastatic Prostate Cancer Guidelines.
Trust Cancer Lead Clinician
The PRIAS Study In Australia One Institution’s Experience Introduction PRIAS (Prostate cancer Research International: Active Surveillance – NTR1718) is.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
PROSTATE CANCER LETS DEBATE !!!! Dr Fred C Tyler MBChB FRCS FCS UROL.
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
 These slides were extracted from a larger set of comprising a presentation entitled “Comparing Treatment Results of PROSTATE CANCER” dated 15_01_2013(3).
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
Cancer Networks: Moving forward Pat Higgins Director of Merseyside and Cheshire Cancer Network.
Teenagers and Young Adults with Cancer Chemotherapy Conference 19 th March 2009 Linda Devereux Associate Director.
Survivorship Update January 2015 The Royal Wolverhampton NHS Trust James Owen Senior Cancer Services Manager.
Prostate Cancer Case Presentation Shireen Siddiqui.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Cancer Commissioning Toolkit and the Somerset Cancer Register Jon Hayes Deputy Network Director.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
Skin Cancer Network Group Audit of Clinical Performance Indicators: Data quality and treatment quality Anna Murray BSc Cancer Information Analyst
Analysis of Patient Experience of Cancer Care Pathway within Merseyside & Cheshire Produced by Merseyside and Cheshire Cancer Network Presented: November.
EUROPA UOMO European Prostate Passport Recommendations from Berlin
PROSTATE CANCER: RADIATION THERAPY APPROACHES ANDREW L. SALNER, MD FACR DIRECTOR HELEN & HARRY GRAY CANCER CENTER HARTFORD HOSPITAL, CT.
Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
ACUTE ONCOLOGY SERVICE MODELS
Urological Cancer Kieran Jefferson Consultant Urological Surgeon
GASTRIC CANCER JHH Johns Hopkins Hospital Gastric Cancer , All Cases n=317 Analytic - Initially Diagnosed and/or received all or.
Network Patient Satisfaction Survey Gloria Payne, Patient & Carer Involvement Facilitator Ian Connolly, Performance Improvement Manager Lead Nurse Open.
Trends in prostate cancer and its management in the South West Region, Hampshire and the Isle of Wight Christine Harling Julia Verne (SWPHO) Roy Maxwell.
New developments in Prostate Cancer Dr Jo Bowen Consultant Oncologist Worcestershire Royal Hospital.
Life after Prostate Cancer and its treatment Mr Sanjeev Pathak Consultant Urological Surgeon and Cancer Lead Doncaster and Bassetlaw NHS Trust 12 th March.
JHH Prostate Cancer Prostate Cancer Cases Diagnosed 1999 – 2004 Analytic vs. Non-Analytic n=7776 * Analytic - Initially Diagnosed and/or received.
Prostate Cancer David Eedes 11 May Prostate Cancer Definition: Prostate cancer is a disease in which cells in the prostate gland become abnormal.
RECTAL CARCINOMA AND PREOPERATIVE MRI: USING A NATIONAL DATASET FOR REGIONAL AUDIT South West Cancer Intelligence Service J Weeks
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.
RCR Bladder Cancer Radiotherapy Audit 2016
Bladder Cancer R. Zenhäusern.
Per-Anders Abrahamsson Department of Urology Malmö University Hospital
New developments in Prostate Cancer
Volume 155, Issue 3, Pages (March 1996)
Surgical Treatment in Locally Advanced Prostate Cancer
Updates in Prostate Cancer Prepared for GP master class – Sept 2016
Bladder Cancer and Prostatic Cancer
Analysis of referral patterns and regional neuro-oncology multi-disciplinary team decisions in brain metastasis Dr Kamalram THIPPU JAYAPRAKASH, Dr Javier.
Primary Care Stratified Follow-up of Stable Prostate Cancer Patients
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.
N.N. Alexandrov National Cancer Centre
Dr Tak-Hing Bill WONG Consultant Urologist & Head
Prostate Cancer: Highlights from 2006
Apollo Gleneagles Hospitals,
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Volume 73, Issue 4, Pages (April 2018)
Current Guidelines in the treatment of Prostate Cancer: what is most appropriate for Nigerian patients? Dr Emmanuel Ajibola Jeje BSc. M. B. Ch.B; FMCS;
11C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate Cancer  I.J de Jong, J Pruim, P.H Elsinga, W Vaalburg,
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Oncoforum Urology: Prostate Cancer 2008 at a Glance
A case of localized Prostate Cancer Marije Hamaker.
Standardised follow-up
Presentation transcript:

23/09/2010 Urology Network Meeting Prostate and Bladder Cancer RLU/BGH Joint Clinic Presented by: Dr Z Malik

Clinic began 9 th January patients seen by Dr Malik, Dr Eswar & Dr Robson (as at 04/09/10) 159 patients with Prostate cancer, 28 patients with Bladder cancer Joint Urology Clinic

Prostate Cancer ~ Staging n=159 TNM Staging at Presentation to CCONo. Patients% Patients T1 – 1c T2 – 2c T3 – 3b T410.6 T? M021.3 M Not Recorded10.6 Recurrence31.9 Progressive21.3 Total159100

Prostate Cancer ~ Treatment for Tumour n=154 Treatment (including planned)No. Patients% Patients Surgery Surgery, hormones, radical radiotherapy31.9 Surgery, radical radiotherapy10.6 Surgery, palliative radiotherapy10.6 Hormones, radical radiotherapy Radical radiotherapy85.1 Brachytherapy127.8 Chemotherapy10.6 Stampede Trial63.9 Hormones Surveillance Bisphosphonate10.6 Patient deciding159.7 Total154100

Relevant PSA Before Treatment Recorded for 133 out of 154 patients with new tumour status Minimum: 0.03 Maximum: 121 Median: 8.2

Prostate Cancer ~ Treatment for Recurrence & Progressive Tumours n=5 RecurrenceNo. Patients Observation1 Radical radiotherapy1 Hormones, prophylactic radiotherapy 1 Total3 ProgressiveNo. Patients Trial (another hospital)1 Palliative radiotherapy1 Total2

Bladder Cancer ~ Staging TNM Staging at Presentation to CCO No. Patients% Patients T2 – 2a725 T3 – 3b T T? M013.6 M Not Recorded13.6 Progressive13.6 Total28100

Bladder Cancer ~ Treatment Treatment (including planned)No. Patients% Patients Surgery517.9 Surgery, radical radiotherapy13.6 Surgery, chemotherapy, radical radiotherapy13.6 Surgery, palliative radiotherapy414.3 Neoadjuvant chemotherapy932.1 Neoadjuvant chemotherapy, concurrent chemoradiation13.6 Neoadjuvant chemotherapy, palliative radiotherapy13.6 Palliative chemotherapy310.7 Radical radiotherapy13.6 None (1 pt other tumour)27.1 Total patients underwent TURBT between December 2008 and January 2010

23/09/2010 Urology Network Meeting Prostate and Bladder Cancers ~ New Referrals to CCO Presented by: Dr Z Malik

Referred between 1 st August 2009 and 31 st July 2010 with new tumour: 712 prostate 134 bladder Prostate and Bladder Cancer

Prostate Cancer

Referring Hospitals ~ 1 st August 2009 to 31 st July 2010 North Royal Liverpool & Broadgreen Walton30.9 Aintree Southport & Ormskirk St Helens & Knowsley Nobles Total South Countess of Chester North Cheshire Wirral Total359100

Prognostic Groups (UICC 2009) GroupFeatures 1T1/T2a N0 M0 PSA<10 Gleason 6 2AT1/T2a/b N0 M0 PSA<20 Gleason 6/7 2BT2c N0 M0 any PSA any Gleason or T1/2 N0 M0 PSA20+ and/orGleason8+ 3T3a/b N0 M0 any PSA, any Gleason 4T4 N0 M0 any PSA any Gleason or Tx N1 M0 or Tx Nx M1

Prognostic Groups Group1; Good Prognosis Group2a; Intermediate Prognosis Group2b; mainly poor prognosis but includes T2c Gleason 6/low PSA Group3; T3s, poor prognosis Group4; T4 and metastatic

South ~ Prognostic Group vs Treatment at CCO (excludes patients who had a prostatectomy) 12A2B34Total Hormones Hormones+XRT XRT alone Brachy* Monitoring Palliative XRT

12A2B34NRTotal Hormones Hormones+X RT XRT alone Brachy* Monitoring Palliative XRT North ~ Prognostic Group vs Treatment at CCO (excludes patients who had a prostatectomy)

Patients who had a Prostatectomy Prognostic Grouping SouthGroup IGroup IIAGroup IIBGroup IIIGroup IV Other Hormones, radical xrt1 Radical xrt112 None312 Prognostic Grouping NorthGroup IGroup IIAGroup IIBGroup IIIGroup IV Other Hormones, radical xrt Radical xrt111 None1

North + South ~ Relevant PSA Before Treatment Recorded 666 out of 712 patients Minimum: 0.13 Maximum: 7960 Median: 11.6